U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H20N6O3
Molecular Weight 440.454
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANDESARTAN

SMILES

CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(O)=O

InChI

InChIKey=HTQMVQVXFRQIKW-UHFFFAOYSA-N
InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)

HIDE SMILES / InChI

Molecular Formula C24H20N6O3
Molecular Weight 440.454
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.japsonline.com/admin/php/uploads/290_pdf.pdf

Candesartan is classified as an angiotensin II receptor type 1 antagonist. Candesartan is an orally active lipophilic drug and possesses rapid oral absorption. It causes a reduction in blood pressure and is used in the treatment of hypertension. It is also used in the treatment of congestive heart failure and given as prophylaxis to reduce the severity and duration of migraine. Candesartan cilexetil, a prodrug of Candesartan, is available in the market under the trade names Atacand, Amias. Candesartan cilexetil is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS (renin–angiotensin–aldosterone system). RAAS is a homeostatic mechanism for regulating hemodynamics, water, and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering the cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2.

CNS Activity

Curator's Comment: Candesartan crosses the blood-brain barrier poorly.

Originator

Curator's Comment: TCV-116 # Takeda, Osaka, Japan

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ATACAND

Approved Use

Candesartan Cilexetil Tablets are an angiotensin II receptor blocker (ARB) indicated for: •Treatment of hypertension in adults and children 1 to < 17 years of age (1.1). •Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to < 17 years of age. It may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Candesartan cilexetil tablets is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see CLINICAL STUDIES (14.2)

Launch Date

8.9691842E11
Primary
ATACAND

Approved Use

Candesartan Cilexetil Tablets are an angiotensin II receptor blocker (ARB) indicated for: •Treatment of hypertension in adults and children 1 to < 17 years of age (1.1). •Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to < 17 years of age. It may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Candesartan cilexetil tablets is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see CLINICAL STUDIES (14.2)

Launch Date

8.9691842E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
92 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
61 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
79 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
55 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1152 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
509 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1359 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
485 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.7 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.1 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.7 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CANDESARTAN CILEXETIL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
unknown, unknown
CANDESARTAN CILEXETIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Co-administed with::
amlodipine(10 mg/day)
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hepatitis...
AEs leading to
discontinuation/dose reduction:
Hepatitis (acute, 1 patient)
Sources:
32 mg 1 times / day steady, oral
Highest studied dose
Dose: 32 mg, 1 times / day
Route: oral
Route: steady
Dose: 32 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 6
Health Status: unhealthy
Condition: Type 2 Diabetes
Age Group: 59 years
Population Size: 6
Sources:
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Disc. AE: Hypotension, Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hypotension (4.1%)
Hyperkalemia (2.4%)
Sources:
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy
Other AEs: Disorder fetal...
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache (0.6%)
Dizziness (0.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatitis acute, 1 patient
Disc. AE
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Co-administed with::
amlodipine(10 mg/day)
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: F
Population Size: 1
Sources:
Hyperkalemia 2.4%
Disc. AE
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Hypotension 4.1%
Disc. AE
23 mg 1 times / day steady, oral (mean)
Recommended
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
unhealthy, 67 years
n = 207
Health Status: unhealthy
Condition: heart failure
Age Group: 67 years
Sex: M+F
Population Size: 207
Sources:
Disorder fetal
16 mg 1 times / day steady, oral
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy
Dizziness 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
Headache 0.6%
Disc. AE
2 mg 1 times / day steady, oral
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 2350
Health Status: unhealthy
Population Size: 2350
Sources:
PubMed

PubMed

TitleDatePubMed
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
1999 Feb
Pharmacological differences among angiotensin II receptor antagonists.
2001
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
2001
[Angiotensin I receptor blockers for heart failure].
2001
[Angiotensin receptor blockers--significance for the therapy of hypertension].
2001
Angiotensin II AT(1) receptor antagonists and platelet activation.
2001
The comparative pharmacology of angiotensin II receptor antagonists.
2001
The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
2001
Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
2001 Apr
Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes.
2001 Apr
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
2001 Apr
Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats.
2001 Apr
Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver.
2001 Apr 27
Functional role of endogenous endothelin-1 in congestive heart failure treated with angiotensin II receptor antagonist.
2001 Aug
Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.
2001 Feb
Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
2001 Feb
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
2001 Feb 1
Effect of prolonged nitric oxide synthesis inhibition on plasma fibrinogen concentration in rats.
2001 Jan
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
2001 Jan-Feb
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
2001 Jul
Angiotensin II activates the GFAT promoter in mesangial cells.
2001 Jul
Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma.
2001 Jul 17
Possible roles of cardiac chymase after myocardial infarction in hamster hearts.
2001 Jun
Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors.
2001 Jun
Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation.
2001 Jun
Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats.
2001 Jun
[Angiotensin II receptor antagonists: different or equivalent?].
2001 Jun 16-23
Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury.
2001 Mar
The influence of chronic antihypertensive treatment on the central pressor response in SHR.
2001 Mar
Antihypertensive effects of losartan and candesartan.
2001 Mar
Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective.
2001 Mar
Combination treatment effective option for hypertensive, diabetic patients with microalbuminuria.
2001 Mar 20
An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion.
2001 May
Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats.
2001 May
Role of cardiac ATP-sensitive K+ channels induced by angiotensin II type 1 receptor antagonist on metabolism, contraction and relaxation in ischemia-reperfused rabbit heart.
2001 May
Tight binding of the angiotensin AT(1) receptor antagonist.
2001 May 15
Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.
2001 May-Jun
Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
2001 Nov
Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis.
2001 Nov
Do vascular compartments differ in the development of chronic rejection? AT(1) blocker candesartan versus Ace blocker enalapril in an experimental heart transplant model.
2001 Oct
Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure.
2001 Oct
Role of AT1 and AT2 receptor subtypes in salt-sensitive hypertension induced by sensory nerve degeneration.
2001 Oct
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.
2001 Oct
TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats.
2001 Oct
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
2001 Oct
ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts.
2001 Oct 12
Angiotensin II induces circadian gene expression of clock genes in cultured vascular smooth muscle cells.
2001 Oct 9
Patents

Sample Use Guides

Adult Hypertension: 2 DOSAGE AND ADMINISTRATION 2.1 Adult Hypertension The usual recommended starting dose of ATACAND (candesartan cilexetil) is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. ATACAND can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg. Pediatric Hypertension 1 to < 17 Years of Age: Children 1 to < 6 years of age: The dose range is 0.05 to 0.4 mg/kg per day. The recommended starting dose is 0.20 mg/kg (oral suspension). Children 6 to < 17 years of age: For those less than 50 kg, the dose range is 2 to 16 mg per day. The recommended starting dose is 4 to 8 mg. For those greater than 50 kg, the dose range is 4 to 32 mg per day. The recommended starting dose is 8 to 16 mg. Adult Heart Failure: The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.
Route of Administration: Oral
Primary cultures of human retinal endothelial cells (EC) were candesartan treatment (1μg/ml).
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:16:27 UTC 2023
Edited
by admin
on Wed Jul 05 23:16:27 UTC 2023
Record UNII
S8Q36MD2XX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANDESARTAN
HSDB   INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
Candesartan [WHO-DD]
Common Name English
CV-11974
Code English
CANDESARTAN [VANDF]
Common Name English
CANDESARTAN [USAN]
Common Name English
NSC-759858
Code English
BLOPRESS
Brand Name English
CANDESARTAN [MI]
Common Name English
CANDESARTAN CILEXETIL RELATED COMPOUND G
USP-RS  
Common Name English
candesartan [INN]
Common Name English
CANDEMORE
Brand Name English
CANDESARTAN CILEXETIL RELATED COMPOUND G [USP-RS]
Common Name English
CANDESARTAN [HSDB]
Common Name English
1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID, 2-ETHOXY-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Common Name English
CANDESARTAN CILEXETIL IMPURITY G [EP IMPURITY]
Common Name English
2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLIC ACID
Common Name English
Classification Tree Code System Code
WHO-VATC QC09DB07
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
WHO-VATC QC09CA06
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
WHO-ATC C09CA06
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
NDF-RT N0000000070
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
WHO-ATC C09DA06
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
NCI_THESAURUS C66930
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
NDF-RT N0000175561
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
WHO-ATC C09DX06
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
WHO-VATC QC09DA06
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
WHO-ATC C09DB07
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
LIVERTOX NBK548409
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
Code System Code Type Description
EVMPD
SUB06070MIG
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
MERCK INDEX
M3012
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY Merck Index
INN
7239
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
ChEMBL
CHEMBL1016
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
WIKIPEDIA
CANDESARTAN
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
ChEMBL
CHEMBL1014
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
LACTMED
Candesartan
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
MESH
C081643
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
HSDB
7520
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
PUBCHEM
2541
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
IUPHAR
587
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
NSC
759858
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
DAILYMED
S8Q36MD2XX
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
DRUG BANK
DB00796
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
CHEBI
149509
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
NCI_THESAURUS
C65284
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
RXCUI
214354
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID0022725
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
CHEBI
3347
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
RS_ITEM_NUM
1087870
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
SMS_ID
100000081620
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
USAN
JJ-6
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
FDA UNII
S8Q36MD2XX
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
CAS
139481-59-7
Created by admin on Wed Jul 05 23:16:27 UTC 2023 , Edited by admin on Wed Jul 05 23:16:27 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
PLASMA; URINE
Related Record Type Details
IMPURITY -> PARENT
Priority toxic pollutant.
IMPURITY -> PARENT
Probable human carcinogen.
PARENT -> IMPURITY
for the calculation of content, multiply the peak area by 0.7.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY GENOTOXIC->PARENT
NDMA is an organic chemical that is in a family of potent carcinogens.
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC